Sign up to Forward: news, insights and features from Mewburn Ellis
Over 60 countries provide extensions for pharma and life sciences patents – more than half of them in Europe. They’re incredibly important in helping to compensate for the years of delay in getting a product through clinical trials and regulatory reviews.
In this Special Report, we focus specifically on the European form of extensions known as “Supplementary Protection Certificates” or “SPCs”.
Having compiled and analysed real-world data, this Special Report sets out to provide valuable insights into the following questions that may face decision-makers handling SPC protection for a new drug:
To receive a copy of the Special Report, please complete the form on the right.